A photo of Sophie standing in front of her poster at the ESMO conference 2025

Dr Sophie Merrick (@drsophiemerrick.bsky.social) presented at #ESMO25 results from her qualitative study within the RAMPART #ClinicalTrial.

Her research highlights how immunotherapy impacts the lives of kidney cancer patients, an essential view in cancer care.

🔗 View the poster: buff.ly/fPtvyZ2

03.11.2025 11:34 — 👍 5    🔁 1    💬 0    📌 0

A combination of two immunotherapy drugs benefits people with kidney cancer | MRC Clinical Trials Unit at UCL

📈 Exciting news from #ESMO25!

First results from the RAMPART trial show that a combination of 2 immunotherapy drugs (durvalumab and tremelimumab) helps prevent kidney cancer from coming back after surgery.

🔗 Read the full story: www.mrcctu.ucl.ac.uk/news/news-st...

21.10.2025 08:15 — 👍 1    🔁 1    💬 0    📌 0

A card with a quote from Sophie, it reads, "I'm proud that the work we're doing helps people with cancer live better, not just longer. The REFINE trial, for example, is focused on improving patients' quality of life and making cancer treatment more accessible and equitable around the world."

Another Wednesday, another chance to share what makes us proud! 😊

This week, we’re spotlighting Sophie Merrick drsophiemerrick.bsky.social, one of our Senior Clinical Research Fellows at the Unit.

Here’s what Sophie is #ProudestOf from the Unit’s work 👇

06.08.2025 08:07 — 👍 4    🔁 1    💬 1    📌 0

💻 Come along to our next Capacity Strengthening Hub webinar with @tghn-news.bsky.social to hear about experts' experience, general principles and a practical framework for communicating #ClinicalTrials results with participants.

🗓️ 2 June
🕙 10:00-11:30 BST
📍 Online

Register now: bit.ly/4k28ALd

05.05.2025 11:02 — 👍 2    🔁 3    💬 0    📌 0

Associate Principal Investigator Scheme - Schedule Next lecture

Join us for our next @NIHRresearch
Learning Lecture 'Making Clinical Trials More Inclusive' with @kamleshkhunti

⏰ 11th June 1-2pm
🖥️ Online
💷 Free

Sign up 👇
sites.google.com/nihr.ac.uk/a...

16.05.2025 10:14 — 👍 0    🔁 0    💬 0    📌 0

'The words "tolerable" or "tolerability" should not be used unless quality of life data are reported' #QoLConf25

12.05.2025 11:20 — 👍 1    🔁 0    💬 0    📌 0

Pleased to share our most recent paper on 'Determining the optimal use of approved drugs in oncology' which is now published in Lancet Oncology. Check it out h👇

07.05.2025 11:30 — 👍 0    🔁 0    💬 0    📌 0

Associate Principal Investigator Scheme - Schedule Next lecture

Join us next week for our free @nihr.bsky.social webinar 'Clinical trials aimed at optimising approved drugs'

⏰ Thursday 20.2.25 1-2pm
💷 Free
👇 Sign up here

@mrcctu.bsky.social

sites.google.com/nihr.ac.uk/a...

10.02.2025 21:40 — 👍 3    🔁 1    💬 0    📌 0

Are you a member of a Research Ethics Committee in the UK? If so, we'd love to speak to you about your views of personalised trials in mental health. Please do consider signing up. #ResearchEthics #MentalHealth

07.02.2025 11:35 — 👍 1    🔁 2    💬 0    📌 0

This is brilliant news for the post NCRI oncology world

07.02.2025 15:24 — 👍 6    🔁 2    💬 0    📌 0

Fraudulent Participation in Online Qualitative Studies: Practical Recommendations on an Emerging Phenomenon This paper offers a critical reflection thereon by three separate qualitative research groups that experienced fraudulent participation in collaboration with a patient representative, a bioethicist, a legal expert, a journal deputy editor, and a chief executive of a national charity.

Fraudulent participation is when study participants purposely give false responses. This can be common in qualitative studies using online recruitment & monetary incentives.

The P-FROST recommendations provide advice on this emerging phenomenon.👇https://buff.ly/4j2qYnl @drsophiemerrick.bsky.social

16.01.2025 12:00 — 👍 1    🔁 1    💬 0    📌 0

Developing a knowledge transfer and exchange strategy for a clinical trials unit - Trials Need for a strategic approach to knowledge transfer and exchange Late-phase clinical trials and systematic reviews find results that have the potential to improve health outcomes for people. However, ...

Late-phase clinical trials have the potential to improve health, but there are often delays in these results influencing clinical practice. We developed a knowledge transfer and exchange strategy to help reduce these delays and maximise impact link.springer.com/article/10.1...

06.01.2025 08:49 — 👍 4    🔁 2    💬 0    📌 0